Introduction
In children with congenital hypothyroidism (CH), thyroid hormone deficiency is present from the prenatal period onward until adequate thyroxine (T4) supplementation is provided after birth. Because thyroid hormone is essential for brain development, these children are at risk for brain damage and subsequent cognitive and motor deficits. [1] [2] [3] The early postnatal start of T4 supplementation, enabled by neonatal screening programs, aims to minimize this brain damage. Several studies on the effect of these screening programs showed that early T4 supplementation resulted in intelligence quotients within the normal range. However, subtle cognitive and motor deficits like attention and balance problems remain present in the majority of patients. [4] [5] [6] [7] [8] [9] To optimize the effect of early treatment on cognitive and motor outcome in CH patients, timing and treatment modality have been adapted several times over the years. For example, treatment modality gradually changed from a relatively low initial T4 dose in the early years of neonatal screening, to higher initial T4 dose in recent years. 10;11 Despite the progress made in terms of standardization of screening procedures and improvements in time and in dose at starting treatment, 10;12;13 controversy still exists worldwide as to the effect of these procedural changes on development. 4;10;11;14-21 Some researchers claim that early treatment with high T4 dose leads to normal brain development; 14;22 others state that timing does not affect cognitive and motor development positively. 4;16;19;23 Therefore, the optimal treatment modality for children with CH is still in debate worldwide.
In The Netherlands, our nationwide study analyzed the effect of the changes in timing and treatment modality over the years by including 3 different cohorts of patients. Phase I of this study investigated cognitive and motor outcome of CH patients born in 1981 through 1982 at 20 years of age 20 and phase II investigated patients born in 1992-93 at 10 years of age. 4 Patients with CH, tested at 20 and 10 years had significantly lower full-scale intelligence quotient (IQ) scores than the norm population and worse motor scores compared with controls. Both intellectual and motor outcomes were most severely affected in patients with severe CH. We concluded that severity of CH was an important factor determining long-term cognitive and motor outcomes. Surprisingly, we did not find evidence for influence of timing of early treatment on intellectual and motor functioning. However, median age at start of treatment was 28 days and 20 days after birth in the phase I 20 and phase II 4 cohorts respectively. So, it could not be ruled out whether earlier start of treatment would have had a beneficial effect.
Therefore we investigated CH patients who were treated at a median age of 9 days after birth (Phase III). Furthermore, we were able to gather more information about treatment in phase III than in the phase I and phase II cohorts, like initial T4-dose and adequacy of treatment because the study started immediately after birth.
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Cognitive and motor development was investigated at 1 and 2 years of age in the present study and compared with normative data. Changes over time were analyzed and outcome was investigated in relation to treatment variables (starting day of T4 supplementation, initial T4 dose and treatment adequacy) and severity of CH based on the pretreatment FT4 concentration:
severe CH: initial FT4≤0.4ng/dL (≤5 pmol/L); moderate CH, 0.4<initial FT4≤0.8ng/dL (5.0<initial FT4≤10.0pmol/L); or mild CH: initial FT4>0.8ng/dL (>10.0 pmol/L).
Methods
Screening method
The Dutch neonatal CH screening method is primarily based on the measurement of T4 in filter paper blood spots. Sampling is performed between 4 and 7 days after birth. The midwife pays a home visit and performs the heel puncture (also for those children born in the hospital, heel puncture is performed between day 4 and day 7 The referral criteria were as follows: if T4 was ≤-3.0 SD or TSH was ≥50mIU/L, children were immediately referred to a pediatrician by the Dutch Health Administrations (DHA). In children with a dubious result (-3.0<T4≤-0.8 SD in combination with a T4/TBG ratio ≤8.5 and/ or 20≤TSH<50 mIU/l), a second heel puncture was performed. Children were referred after a second heel puncture if the result was dubious again or abnormal. The diagnosis of CH and its etiological classification was based upon initial presentation, thyroid function determinants and a full set of thyroid imaging.
Patient recruitment
The study was coordinated and executed by the department of pediatric endocrinology This enabled the researchers of the AMC to immediately contact the pediatrician to 75 
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Subsequently, the pediatrician was provided with information by letter or fax. This included detailed written information for the parents, and their invitation to participate in the study.
In some children, the diagnosis of CH was established incidentally by the AMC, for example, when their urine or blood was sent for diagnostic work-up. Parents of these patients were also invited for the study. They received with written study information via their pediatricians.
Patients
The In the present study, parents of 16 children did not give their informed consent. In addition, 76 patients were considered 'not suitable' for the following reasons: CH-C (n=21), CH not yet specified (n=10), CH-T 21 (n=15), Johansson-Blizzard syndrome (n=1), Turner syndrome (n=1), Beckwith-Wiedeman syndrome (n=1), Pendred syndrome (n=1), an undefined syndrome (n=4, delayed initiation of treatment (>2months after birth; n=2)), a severe cardiac defect necessitating long-term hospitalization (n=1), parents who had severe difficulties with the Dutch language (n=6), prematurity (either born<32 weeks GA or birth weight <1.5kg;n=4); 1 patient had died; 1 patient had moved abroad and 7 patients were not treated adequately.
The remaining participants patients with CH-T (n=107), without a remarkable medical history besides their CH, were then classified to subgroups based on the pre-treatment FT4 concentration: 'severe CH': initial FT4≤0.4ng/dL (≤5 pmol/L); 'moderate CH':0.4<initial
'reference range FT4' , 10 to 23 pmol/L (0.78-1.79 ng/dL).
Treatment strategy
During the study period, Dutch pediatricians were advised on treatment modalities and to start with T4 supplementation in a dose of approximately ± 10µg/kg per day in all children, whereas in those children with an initial FT4 concentration <8pmol/L, it was advised to give a single additional dose of 10 µg/kg about 12 hours after the first dose. Some pediatricians followed the guideline introduced in 1997 (i.e. to start with 50µg as an initial dose, followed by 10µg/kg per day for the following days). Dose of T4 was subsequently adjusted according to further thyroid function determinants, which were measured during regular controls at the outpatient clinic, according to international guidelines. In general, children are initially seen twice a week, for 2 to 3 weeks. From then on, the period in between controls is gradually extended to once a month in the first year. In the second year children are seen once every 2 to 4 months.
Treatment adequacy
All FT4 and TSH concentrations during the first 2 years of treatment were evaluated. From these data, we analyzed the day at which FT4 was >12 pmol/L for the first time, and the day . 25 Most patients were tested at the age of 13 and 25 months, so that 4 scores (MDI, PDI at 13 and 25 months) could be used as outcome measure in the present study.
Statistical analysis
Data were analysed using SPSS version 15.0 (SPSS Inc.,Chicago, IL). Chi-square-tests were conducted to test differences between participants and non-participants, regarding gender and diagnosis.
One-sample t tests were performed to test whether the MDI and PDI scores in the different severity CH subgroups differed from the normative value of 100. Paired sample t-tests were used to test the differences over time; MDI and PDI scores at the age of 13 months were compared with those at the age of 25 months.
Analysis of variance (ANOVA) was used to test the differences between the 3 severity groups (severe, moderate and mild) on PDI and MDI mean scores. To adjust for multiple testing, Bonferroni analyses were used. Linear regression analyses were performed to investigate the impact of the following clinical determinants: severity (initial FT4 concentration), starting day of treatment, and initial T4 dose on MDI and PDI at the age of 1 and 2 years. It was not necessary to correct for parental educational level (a potential confounder) because parental educational level appeared to be distributed equally over the subgroups.
The difference in MDI and PDI at the age of 2 years between the adequately and (dubiously) inadequately treated groups was calculated using Mann-Whitney U tests.
Results
Patient characteristics
Of the 107 included toddlers with thyroidal congenital hypothyroidism (CH-T), 19 were considered 'not suitable' because intercurrent illness at the time of psychological assessments (n=1), less than 3 of the 4 BSID-II-NL scores were available (n=11). The remaining 95 were considered the participants at the age of 1 and 2 years.
Participants were classified as CH-T due to thyroid dysgenesis (63.2%), CH-T with normal located thyroid gland (26.3%), or CH-T not yet specified (10.5%), which was different from the distribution of diagnosis in non-participants (see table 1 ). Other baseline characteristics of the participating CH-T patients are given in Table 2 . Of the 95 patients (68 females, 72%), 28 patients (30%) had severe CH-T. Moderate and mild CH-T were seen in 24 (25%) and 43 (45%) patients respectively.
The mean age at start of thyroxine (T4)-supplementation was 10.6 days (median, 9 days; range, 2-32 days). Children with severe and moderate CH-T started significantly earlier with T4 than children with mild CH-T (p=0.0001 and p=0.016 respectively). The mean initial T4 dose was 11.4µg/kg per day (range 5.4-20.1 µg/kg per day).
Developmental outcome in relation to severity
The mental developmental index (MDI) and the psychomotor developmental index (PDI)
scores of the CH patients tested at 1 year (13 months) and 2 years (25 months) are shown in Table 3 . The mean MDI scores of the total, severe, moderate and mild CH-T group at 1 year were similar to the population mean (total: t = 1.034 p = 0.304; severe: t = 0-.530, p = 0.6; moderate: t = 1.341, p = 0.193; mild: t = 0.933, p = 0.356). The mean PDI scores of the total, severe, moderate and mild CH-T group were significantly lower than the population mean at 1 MDI and PDI expressed as mean with con dence interval between parentheses *p<0.05;**p<0.001; ***p<0.0001 di erence between CH patients and normative population (based on one sample t-tests). a p<0.0005 signi cant change over time; di erence between CH patients at 1 year and 2 years of age (based on paired t-test). CH-T: yroidal congenital hypothyroidism. year (Total: t = -7.083, p<0.0001; severe: t = -4.842, p<0.0001; moderate: t = -2.464, p = 0.022; mild: t = -4.847, p<0.0001). The mean MDI score of the total CH-T group and severe CH-T group at 2 years were significantly lower than the population mean (total: t = -2.842 p = 0.006; severe: t = -5.417, p<0.0001), whereas the mean MDI scores of the moderate and mild CH-T group were similar to the population mean (moderate: t = -0.935, p = 0.360; mild: t = 0.058, p = 0.954). At 2 years, the mean PDI scores of the total, severe, moderate and mild CH-T group were significant lower than of the population mean (total: t = -7.747, p<0.0001; severe: t = -6.479, p<0.0001; moderate: t = -3.262, p = 0.004; mild: t = -4.100, p<0.0001).
79
chapter
Evaluation of cognitive and motor development in toddlers with congenital hypothyroidism diagnosed by neonatal screening
Mean MDI scores did differ significantly (p<0.001) at 2 years between the CH-T severity subgroups (F(2.94) = 8.161, whereas PDI scores did not. At 2 years, the MDI scores of the severe CH-T group were significantly lower than those of the mild and moderate CH-T groups (p<0.001;p<0.05, respectively; Table3).
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Change over time
The results of a paired t-test showed a significant decrease over time on the MDI for the total and severe CH groups (t=3.720, df=91, p<.0005, two tailed) ( Table 3 ). The mean difference between the MDI scores over the years was 5.17 and the 95% confidence interval for the estimated population mean difference is between 2.41 and 7.93. There was no significant difference over time on the PDI, (t = 0.816, df = 82, p<.417, two tailed). The mean difference between the PDI scores over the 2 years was -1.41 and the 95% confidence interval for the estimated population mean difference is between -4.84 and 2.03.
Developmental outcome at 1 and 2 years in relation to medical determinants
The multiple regression analyses for MDI and PDI with initial FT4 concentration, starting day of T4 supplementation and initial T4-dose, resulted in a significant model for MDI score at the age of 2 years: F (3.84) = 4.186, p=0.008 (table 4). The model explained 9.9% of the variance.
Initial FT4 concentration contributed significantly to the model, whereas the other variables did not. Starting dose of T4 appeared to be a predictor of MDI at the age of 1 year and of the PDI at the age of 1 and 2 years (table 4). 
Discussion
Our study shows that toddlers with thyroidal congenital hypothyroidism (CH-T), who were screened and treated according to national recommendations and current practice, had subtle deficiencies in cognitive development at 2 years of age. This was most prominent in toddlers with severe CH-T. In addition, toddlers with CH-T had significantly lower psychomotor developmental index (PDI) scores than the population mean at 1 and 2 years of age, irrespective of severity of hypothyroidism.
The most striking result in our study was that no correlation was found between the starting day of treatment (range 2-32 days) and cognitive and motor development. The possible effects of the starting day of treatment, initial dose of thyroxine (T4) and CH-T severity on developmental outcome of patients detected by neonatal CH screening have been object of many studies. 4;11;13;14-21 However, the results are often difficult to compare with each other because screening method, guidelines for treatment (starting day of treatment and initial T4 dose, quality of treatment), sample size, and criteria for CH-T severity differ among these studies. A striking example is that in one study, the same initial starting dose gave a favorable outcome if it was defined as high, 14 and a suboptimal outcome when defined as a low dose. 22 To overcome these limitations, we tested a large cohort of CH-T patients and we used the same psychological tests carried out Apparently, brain development is thyroid hormone dependent not only in the neonatal period but also prior to birth. Apparently, maternal T4, transferred via the placenta, is not sufficient to prevent any brain damage. Possibly the subtle deficits found, might not solely be the result of prenatal thyroid hormone deficiency, and that, for example, inadequate treatment may play a role as well. We made our own definition because an international guideline to define "adequate treatment" is not available. Analysis showed that only a minority of patients during the first or second year of life had >20% of the vena punctures with values deviating from the norm. So, we can conclude that the majority of our patients were adequately treated during their first 2 years of life. Moreover, no differences were found in developmental outcomes between the patients with>20% of blood values deviating from the norm from those with<20% of blood values deviating from the norm.
A limitation of the study is that no definite conclusions can be drawn on the cognitive and motor capabilities of CH patients at older age. The BSID-II-NL is a different test than the IQ tests we used for the 10 year olds. Therefore it is advisable to retest the children at 10 years of age. Another shortcoming of the study is that a control group of age-matched norms was not available. Although including a control group could optimize comparison on motor and mental development next to the normative data, the BSID is a reliable standardized international developmental test, whereby the use of normative data is well accepted. A surprising result in the present study was that the mean mental developmental index (MDI) score of the severe CH patients at the age of 1 year was similar to the population mean, whereas the mean MDI score of the severe patients at the age of 2 years was significant lower than the population mean. Explanations for these findings could be that cognitive problems only become evident at older age. Another explanation could be that the psychological tests used in older children are more sensitive to detect differences or are more reliable than the instruments used in younger children. This explanation is confirmed by the study of Westra et al. 27 They found that the of the test outcomes for future cognitive and motor functioning increases with age. Therefore, it is difficult to draw conclusions based on the outcome at 1 year of age. The norms are more reliable at the age of 2 years. 27 Even if we take the limitations into account, our data are convincing in that children with CH-T, even when treated within a few days after birth, still suffer from subtle cognitive and motor delays. To get more insight into the depth of these delays, it is important to study cognitive and motor functioning of CH-T patients in more detail, for example to examine additional neuropsychological domains like attention and memory and specific motor functioning.
Unfortunately, with the BSID-II, 25 it was not possible to split motor function in specific motor areas. With the new version of the BSID, version III, it is possible to examine motor development more in depth. However this version was not yet available during our inclusion period. Future studies should take in consideration the use of instruments that are able to differentiate between domains of functioning. Reevaluation of these subjects at an older age when domains such as attention and memory can be more accurately assessed will be helpful. 8 Our consistent findings over time warrant for sensitive monitoring of motor functioning.
Pediatricians should be aware of these motor problems to make early identification and intervention possible. Tailored support with respect to movement and sports should be considered as an early intervention. In addition, we recommend referring all children with severe CH-T to a physiotherapist as part of standard health care. Furthermore, our results underscore the importance of monitoring general and language development of toddlers with a severe form of CH-T. Referral for developmental assessment and, if needed, for speech therapy are possible interventions.
Our data strongly indicate that the prenatal hypothyroid state is responsible for the postnatal outcome, and hence, it may be concluded that the current neonatal screening program on CH is optimal, as it is. Future research should focus on improvements of the prenatal thyroid hormone state.
Finally, international guidelines for optimal treatment are desirable and needed. Consensus with respect to treatment (starting day of treatment, initial T4-dose, quality of treatment)
and criteria for CH-T severity are of utmost importance to provide direction for helping children with CH and personalizing their medicine. Therefore, recent literature provides recommendations regarding the treatment of children with CH. 10;11;26;28 Furthermore, promising new guidelines from the European Society for Pediatric Endocrinology (ESPE) are underway, so it is important to take these in consideration in clinical practice and future research, when published. However, pursuing research in this area seems important.
In conclusion, this study has shown subtle cognitive and motor deficits in patients with severe CH, whose treatment with T4 was initiated at a mean age of 10.6 days after birth.
Mildly and moderately affected CH patients had a fair prognosis for mental developmental
